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Co-infections with HBV (hepatitis B virus) occur in HIV (human immunodeficiency virus) patients frequently. It has been
reported that an effective treatment of HIV can also lead to a suppression of HBV and to anti-HBs seroconversion in
HBV-infected patients. Here, we report a spontaneous reactivation of HBV replication in an HIV-infected patient with
anti-HBc as the only marker of chronic HBV infection. The patient was known to be coinfected with HIV and HBV for
years and the HBV DNA was measured repeatedly at low levels. A significant increase of HBV DNA up to 1.7x107 IU/ml
was found accompanied with clinical symptoms of hepatitis. Multiple mutations occurred in the S gene during the
flare-up of HBV as shown by sequencing, including I103T, K122R, M133I, F134V, D144E, V164E and L175S. Anti-HIV/HBV
treatment led to a resolution of symptoms and to a decrease in the HIV RNA and HBV DNA viral load. It is possible that
the accumulated mutations during HBV replication were selected and responsible for the reactivation.
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The hepatitis B virus (HBV) is a double-stranded DNA
virus belonging to the family of Hepadnaviridae, affecting
an estimated 350 million chronically infected individuals
worldwide. Due to the similar transmission routes, HBV
and human immunodeficiency virus (HIV) coinfection is
common and an estimated 5%-15% of HIV infected pa-
tients also have HBV infection [1]. HIV coinfection in-
creases the risk of HBV chronicity and HBV reactivation
as well as the risk for the development of liver cirrhosis
and hepatocellular carcinoma (HCC) [2,3].
Reactivation of a former HBV infection can occur spon-
taneously or triggered by immunosuppressive therapy,
immunocompromising diseases, organ transplantation or
withdrawal of antiviral drugs [4-8]. HBV precore mutation
has been reported to be associated with spontaneous re-
activation of HBeAg positive chronic hepatitis B [9]. The
recurrence of HBV replication in HIV/HBV-coinfected
patients has been described due to the interruption of
lamivudine therapy, due to resistance to the drug [10,11]* Correspondence: rongjuan_pei@wh.iov.cn
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stated.and due to HBV immune-escape or precore mutants
[11-13]. However, little is known about the molecular
characteristics of HBV that is reactivated spontaneously in
HBV/HIV coinfected individuals. Previously, HBsAg im-
mune escape mutants were described in the chronic phase
and a flare-up phase of HBV infection of an HBV/HIV in-
fected person [14]. Here we analyzed the HBV sequence
changes in an HBV/HIV coinfected patient who suffered
from a spontaneous reactivation of HBV.Methods
Serology
Serum samples were stored at −70°C before analysis.
Serological markers of HBV infection were determined
using commercial enzyme immunoassay kits (Abbott
Laboratories, IL, USA) and confirmed partly with other
assays (Roche Diagnostics GmbH, Mannheim, Germany;
Dade Behring GmbH, Marburg, Germany). The HBV
DNA level was quantified using a commercial real-time
fluorescence quantitative kit (Roche) and Versant HBV
bDNA assay kit (Siemens).. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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sequencing of PCR fragments
The HBV DNA was extracted from patient sera using
QIAamp DNA blood mini kit (Qiagen, Hilden, Germany)
and subjected to PCR amplification using the high fidelity
Taq polymerase (Roche) according to the manufacturer’s in-
struction. The region encoding the HBsAg (nt 2818–888)
was amplified using primers FS-S1 5′-GTCACCATATTC
TTGGGAAC-3′ (nt 2818–2837) and FS-AS 5′-CATATCC
CATGAAGTTAAGG-3′ (nt 888–869) according to the ref-
erence sequence AY220698 and cloned into pCR2.1 vector.
Five clones of each sample were sequenced.
Results
Clinical features
A 60-year-old patient was known to be infected with
HIV-1 since 1984. He was diagnosed with a HBV coin-
fection in July 2003 by HBV serology (HBsAg positive,
HBeAg positive and anti-HBc positive) and detectable
HBV DNA in the serum. Between October 2003 and
August 2007 the HBV DNA fluctuated between 10 to
357 IU/ml while the serological markers of HBV except
anti-HBc were negative (Table 1). Since the patient had
no HIV-associated symptoms and stable numbers of
CD4 positive T helper cells > 500/μl (Figure 1B) with a rela-
tively low HIV viremia (< 100,000 copies/ml) he did not re-
ceive a highly active antiretroviral therapy (HAART).
In April 2008 the patient was admitted to hospital due
to an acute icteric hepatitis with elevated serum trans-
aminases (AST and ALT > 1000 U/mL) and cholestasis
(total bilirubin more than 9.2 mg/dl) (Figure 1A). HBV
serologiy (HBsAg, HBeAg and anti-HBc positive) and
PCR (HBV DNA >17.86 million IU/ml) showed an ex-
acerbation of chronic HBV infection. At the same time
the HIV viral load was 53,000 copies/ml (Table 1). The
presence of a co-infection with hepatitis D virus (HDV)
was excluded serologically.
The patient was treated with HIV/HBV-active therapy
(emtricitabine 200 mg, tenofovir 245 mg (Truvada ®) 1-0-0 ,Table 1 Sequential serological and virological findings
Month/year 07.2003 10.2003 08.2004 07.2005 11.2005
HBsAg + - - - -
Anti-HBs ND - - - -
HBeAg + ND ND ND -
Anti-HBe - ND ND ND -
Anti-HBc + + + + +
Anti-HBc-IgM + - - ND -
HBV DNA + - ND + +
1.1 × 105 ND ND 357 357
HIV 2.6 × 104 1.3 × 104 ND 1.5 × 104 1.2 × 104
ND means not detected.lopinavir 200 mg, ritonavir 50 mg (Kaletra ®) 2-0-2 ),
and hereby a rapid virological response was achieved
with HBV and HIV viremia decreasing below the limits
of detection. The response to antiviral therapy was accom-
panied by a clinical improvement of the patient, a
normalization of the transaminases and of the cholestasis
parameters. Anti-HBs seroconversion was achieved 7
months later and was preceded by a phase of simultan-
eous detection of HBsAg and anti-HBs at 4 months
after treatment as it is seen often in clinical routine.
Interestingly in the long term anti-HBs declined below
the detection limit and anti-HBc again remained the
only positive serological HBV marker. During the en-
tire course no significantly change of CD3 + CD4+ T-
lymphocytes and the NK CD3-/CD16/56 was found; the
counts of CD3 + CD8+ and total CD3+ T-lymphocytes
was elevated temporarily after the HAART treatment was
started, and the counts of CD19+ lymphocytes was at low
level likely due to a splenectomy conducted previously
due to a trauma.
HBV mutations in the S and the Pol genes
HBV DNA fragments were amplified from 5 serum sam-
ples, three of which were collected in the early chronic
phase of infection and two were collected during the
flare-up phase, while other samples were negative in the
HBV PCR due to the low HBV viral loads. A HBV geno-
type A HBsAg subtype adw2 strain was found in the
chronic phase and the HBV population was homogenous
at the time of the first diagnosis of HBV infection. How-
ever, the HBV population during the flare-up phase was
found to be heterogeneous with multiple amino acid (aa)
substitutions within the HBsAg a-determinant. Particu-
larly, the subtype determinant aa 122 K was replaced by
R gradually in the flare-up samples. More aa substitu-
tions were found, including I103T, M133I, F134V,
D144E, V164E and L175S in the HBsAg (Table 2) and
T45S, N122D, V133G/N and W144G in the HBV RT se-
quence (Table 3). In contrast, the HBV preC/C region08.2006 08.2007 04.2008 06.2008 08.2008 11.2008
- + + ND + -
- - - ND + +
ND ND + ND ND -
ND ND - ND ND -
+ + + ND + +
ND ND + ND - -
ND + + ND -
ND 1009 1.7 × 107 357 ND <357
1.2 × 104 2.9 × 103 5.3 × 104 1.2 × 102 ND <50
AB
















































































































Figure 1 The ALT, AST, bilirubin levels and lymphocytes counts in an HBV/HIV coinfected patient experiencing a spontaneous HBV
reactivation. (A) The ALT, AST and bilirubin levels were monitored regularly from 2006 to 2009. The ALT and AST levels were plotted at the left
Y-axis and the bilirubin level at the right Y-axis. The insert indicated the ALT, AST and bilirubin levels during the flare-up phase, the black arrows
indicated the sampling time for sequencing. (B) The lymphocytes counts were monitored regularly from 2006 to 2009. The relative CD4+ T cell
counts in the CD3+ T cell population (CD4 +%) was set at the right Y-axis. The black arrow indicated the start of the antiviral therapy.
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the same time period.
Discussion
In the present case anti-HBc was the only detectable
HBV marker (“anti-HBc only status” [15,16]) between
October 2003 and October 2007. The HBV DNA fluctu-
ated between 10 to 357 IU/ml, indicating an occult
chronic HBV infection. Several explanations have been
declared for ‘anti-HBc only’ status, including false posi-
tive detection of anti-HBc, low replication level of HBV,
HBV mutations, coinfection with other viruses and forma-
tion of HBsAg-anti-HBs immune complexes [17]. Anti-HBconly serostatus has been described frequently among
individuals coinfected with HIV or hepatitis C virus
(HCV) infection [18,19]. It is advised to monitor such
patients at regular intervals by HBV serology [15,20]
and the HBV DNA should be investigated in case of el-
evated transaminases [18].
Although about 17-42% of patients coinfected with
HIV/HBV have anti-HBc only, there are few reports on
the reactivation of HBV in these patients [20,21]. Previ-
ously, Chamorro et al. reported on a reactivation of
HBV after the removal of lamivudine in an HIV-infected
patient with anti-HBc as the only serological marker [22].
In the present case, the reactivation of HBV occurred
Table 2 Characterization of HBsAg sequences
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who had not received antiretroviral drugs for years before
the hepatic flare. An interesting finding is that the K to R
mutation at s122 occurred during the flare-up phase and
led to the change of the HBV serotype from adw to ayw.
Most of the other aa substitution in the HBsAg found dur-
ing the flare-up phase described here have been reported
before and in combination with the K122R mutation, pos-
sibly causing HBV escape from anti-HBs. Amino acid sub-
stitutions, which change the hydrophilicity, the electrical
charge or the acidity could change the conformation of
the a-determinant [23]. M133I and D144E mutation were
reported to cause a reduced HBsAg affinity to anti-HBs
[24,25]. F134V mutation was supposed to be a vaccine in-
duced escape mutant [26] and L175S mutation was found
in patients with HBsAg-anti-HBs coexistence [27]. The
replication competence of HBV strains from different time
points need to be compared.
The question was raised whether the hepatitis flare in
this patient could be interpreted as a superinfection.However, this patient was constantly positive for HBV
DNA for many years. The sequence analysis revealed
that the HBV preC/C region was strictly conserved dur-
ing the course of infection, an evidence preferably for re-
activation. Another point for dispute is the fact that
there was no obvious pressure by anti-HBs responses for
the selection of escape mutations. However, Weinberger
et al. [28] indicated that the variability of the major
hydrophilic loop of HBsAg was raised significantly in in-
dividuals with anti-HBc only compared with HBsAg
positive individuals. The patient in this study was posi-
tive for anti-HBc only for a long period and represents a
typical case of such status. The anti-HBc only status dur-
ing the chronic phase might be due to the control of
HBV replication by the immune surveillance and/or due
to the detection escape mutation that may occurred
early in the chronic phase. The mutations may have ac-
cumulated under these pressures and became the dom-
inant strain. In addition, it is possible that the patient
had a low anti-HBs response which remained under the
Table 3 Characterization of HBV RT sequences
45 91 117 122 133 137 139 144 154 159 184 185 214
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anti-HBc IgM in the patient during chronic HBV infec-
tion and in the flare-up phase. Although normally the
appearance of anti-HBc IgM indicates a new infection, it
may also be detected during HBV reactivation [29,30].
Therefore, we could not completely rule out the possi-
bility of superinfection but do not have evidence favor-
ing this hypothesis.
Before the hepatitis flare, the patient did not receive
any antiviral treatment, immunosuppressive therapy, or
radiation treatment, which may be related to HBV re-
activation [31,32]. It seems that the reactivation hap-
pened spontaneously. The accumulation and selection of
HBV escape mutants might be one important factor. On
the other hand, the immune suppression caused by HIV
infection probably also played a role in HBV reactiva-
tion. Previously, interleukin-6 (IL-6) was proven to serve
as the main bystander mediator of radiotherapy induced
HBV replication and IL-6 and radiotherapy have syner-
gistic effect [33]. However, it is not clear whether thecytokine profile was changed in this patient and related
to the reactivation.
In conclusion, we reported on a case of spontaneous
HBV reactivation in an HIV coinfected patient with iso-
lated anti-HBc, in which the escape mutants in s gene
might be responsible for the flare-up. Continued moni-
toring of the patient with respect to HIV and HBV is ne-
cessary for recognizing a possible re-flare of the HBV
infection. Retrospectively, the reactivation of HBV might
already have been diagnosed in August 2007 when
HBsAg and HBV DNA tested positive as indicated from
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